Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 1: 245 - 256

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.01.024

Review

Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders

  • Wu YANG ,
  • Yinghui LI ,
  • Heng LIAO ,
  • Shangbin XIONG
Expand
  • 1 Taihe Hospital Rehabilitation Center, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, China
    2 Department of Ultrasound, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan 442000, China

Received date: 2024-10-23

  Accepted date: 2025-04-22

  Online published: 2026-01-28

Fold

Abstract

Berberine, an isoquinoline quaternary alkaloid, is a molecule with significant therapeutic adaptability. It has been identified, isolated, and measured in a wide range of plant families and species. Of these, Berberis stands out as a significant natural source of berberine, with Berberis vulgaris (B. vulgaris) bark being one of the most notable. The numerous health benefits associated with berberine include its potential use in the treatment of diseases, such as cancer, cardiovascular diseases, diabetes, and neurological disorders. The principal use of berberine has been for its antidiarrheal properties, which may have several modes of action. Its potent antioxidant and anti-inflammatory effects are responsible for its preventive action against stomach ulcers, and it has been found to kill dangerous gut bacteria while boosting the species and numbers of health-promoting bacteria. It protects the colon by influencing the production of several immune factors in addition to upregulating the Wnt-β creatinine signaling cascade. Berberine has shown its potential in regulating cholesterol metabolism by elevating the levels of low-density lipoprotein receptor in the liver. This review comprehensively examines the pharmacokinetics, multifaceted bioactivities, and gut-protective roles of berberine, providing a detailed analysis of its diverse physiological functions and potential clinical applications to advance the understanding and management of gastrointestinal diseases.

Key words： berberine; gastrointestinal tract; antineoplastic agents; anti-ulcer agents; review; natural compound

Cite this article

Wu YANG , Yinghui LI , Heng LIAO , Shangbin XIONG . Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders[J]. Journal of Traditional Chinese Medicine, 2026 , 46(1) : 245 -256 . DOI: 10.19852/j.cnki.jtcm.2026.01.024

References

1. Zhang LC, Wu XY, Yang RB, et al. Effects of berberine on the gastrointestinal microbiota. Front Cell Infect Microbiol 2021; 10: 588517.
2. Wang YW, Zidichouski JA. Update on the benefits and mechanisms of action of the bioactive vegetal alkaloid berberine on lipid metabolism and homeostasis. Cholesterol 2018; 2018: 7173920.
3. Fan J, Zhang K, Jin Y, et al. Pharmacological effects of berberine on mood disorders. J Cell Mol Med 2019; 23: 21-8.
4. Wolf PG, Devendran S, Doden HL, et al. Berberine alters gut microbial function through modulation of bile acids. BMC Microbiol 2021; 21: 24.
5. Izadparast F, Riahi-Zajani B, Yarmohammadi F, Hayes AW, Karimi G. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle 2022; 21: 2365-78.
6. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22: 999-1012.
7. Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol 2012; 84: 1260-7.
8. Huang L, Luo ZH, He F, Shi AD, Qin FF, Li XS. Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase. Bioorg Med Chem Lett 2010; 20: 6649-52.
9. Ma Y, Ou TM, Tan JH, et al. Synthesis and evaluation of 9-O-substituted berberine derivatives containing aza-aromatic terminal group as highly selective telomeric G-quadruplex stabilizing ligands. Bioorg Med Chem Lett 2009; 19: 3414-7.
10. Zhang WJ, Ou TM, Lu YJ, et al. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA. Bioorg Med Chem 2007; 15: 5493-501.
11. Chen WH, Pang JY, Qin Y, Peng Q, Cai Z, Jiang ZH. Synthesis of linked berberine dimers and their remarkably enhanced DNA-binding affinities. Bioorg Med Chem Lett 2005; 15: 2689-92.
12. Neag MA, Mocan A, Echeverría J, et al. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol 2018; 9: 557.
13. Andola HC, Gaira KS, Rawal RS, Rawat MS, Bhatt ID. Habitat-dependent variations in berberine content of Berberis asiatica Roxb. ex. DC. in Kumaon, Western Himalaya. Chem Biodivers 2010; 7: 415-20.
14. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010; 24: 317-24.
15. Rashmi, Rajasekaran A, Pokhriyal R, Singh YP. Quantitative estimation of berberine in roots of different provenances of Berberis aristata DC by HPLC and study of their antifungal properties. Pharmacognosy Magazine 2009; 5: 355-8.
16. Zhu CP, Li KQ, Peng XX, et al. Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy. Front Immunol 2022; 13: 1083788.
17. Li ZY, Wang Y, Xu Q, et al. Berberine and health outcomes: an umbrella review. Phytother Res 2023; 37: 2051-66.
18. Hou Q, He WJ, Wu YS, Hao HJ, Xie XY, Fu XB. Berberine: a traditional natural product with novel biological activities. Altern Ther Health Med 2020; 26: 20-7.
19. Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero AFG, Pirro M, Sahebkar A. Regulatory effects of berberine on microRNome in Cancer and other conditions. Crit Rev Oncol Hematol 2017; 116: 147-58.
20. Su YH, Tang WC, Cheng YW, et al. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer. Biochim Biophys Acta 2015; 1853: 2261-72.
21. Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol 2012; 35: 57-70.
22. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J Ethnopharmacol 1999; 66: 227-33.
23. Kalaiarasi A, Anusha C, Sankar R, et al. Plant isoquinoline alkaloid berberine exhibits chromatin remodeling by modulation of histone deacetylase to induce growth arrest and apoptosis in the A549 cell line. J Agric Food Chem 2016; 64: 9542-50.
24. Yang XL, Huang N. Berberine induces selective apoptosis through the AMPK-mediated mitochondrial/caspase pathway in hepatocellular carcinoma. Mol Med Rep 2013; 8: 505-10.
25. Jeong SY, Seol DW. The role of mitochondria in apoptosis. BMB Rep 2008; 41: 11-22.
26. Park GB, Park SH, Kim D, Kim YS, Yoon SH, Hur DY. Berberine induces mitochondrial apoptosis of EBV-transformed B cells through p53-mediated regulation of XAF1 and GADD45α. Int J Oncol 2016; 49: 411-21.
27. Zhang XL, Gu LB, Li JS, et al. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 2010; 70: 9895-904.
28. Zhuang W, Li T, Wang CJ, et al. Berberine exerts antioxidant effects via protection of spiral ganglion cells against cytomegalovirus-induced apoptosis. Free Radic Biol Med 2018; 121: 127-35.
29. Hassani-Bafrani H, Najaran H, Razi M, Rashtbari H. Berberine ameliorates experimental varicocele-induced damages at testis and sperm levels; evidences for oxidative stress and inflammation. Andrologia 2019; 51: e13179.
30. Li ZM, Jiang T, Lu Q, et al. Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells. Cell Mol Neurobiol 2020; 40: 587-602.
31. Guna V, Saha L, Bhatia A, Banerjee D, Chakrabarti A. Anti-oxidant and anti-apoptotic effects of berberine in pentylenetetrazole-induced kindling model in rat. J Epilepsy Res 2018; 8: 66-73.
32. Dkhil MA, Metwaly MS, Al-Quraishy S. Berberine improves the intestinal antioxidant status of laboratory mice, mus musculus. Saudi J Biol Sci 2017; 24: 1567-73.
33. Wang HR, Zhu C, Ying Y, Luo LY, Huang DQ, Luo ZJ. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget 2017; 9: 10135-46.
34. An Y, Sun ZZ, Zhang YJ, Liu B, Guan YY, Lu MS. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf) 2014; 80: 425-31.
35. Li Y, Kuang HY, Shen WJ, et al. Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial. BMJ Open 2013; 3: e003934.
36. Li MF, Zhou XM, Li XL. The Effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): a Meta-analysis and systematic review. Evid Based Complement Alternat Med 2018; 2018: 2532935.
37. Cicero AF, Reggi A, Parini A, et al. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev 2014; 21: 221-6
38. Shu JX, Zhong CS, Shi ZJ, et al. Berberine augments hypertrophy of colonic patches in mice with intraperitoneal bacterial infection. Int Immunopharmacol 2021; 90: 107242.
39. Gao Y, Wang FX, Song YJ, Liu HB. The status of and trends in the pharmacology of berberine: a bibliometric review 1985-2018. Chin Med 2020; 15: 7.
40. Chen CQ, Yu Z, Li YY, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. Am J Chin Med 2014; 42: 1053-70.
41. Chen CQ, Lu ML, Pan QH, et al. Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One 2015; 10: e0145556.
42. Li L, Cui HR, Li T, et al. Synergistic effect of berberine-based Chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo. Front Pharmacol 2020; 11: 1210.
43. Chen CQ, Tao CH, Liu ZC, et al. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res 2015; 29: 1822-7.
44. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014; 2014: 289264.
45. Guo QY, Lu TM, Zhang M, et al. Protective Effect of berberine on acute gastric ulcer by promotion of tricarboxylic acid cycle-mediated arachidonic acid metabolism. J Inflamm Res 2024; 17: 15-28.
46. Liu WZ, Yang XZ, Nie ZW, Yin HM, Xie Y. Effect of berberine on gastric mucosa of gastritis model rats induced by Helicobacter Pylori. Revista Cientifica-facultad De Ciencias Veterinarias 2020; 30:1696.
47. Pan LR, Tang Q, Fu Q, Hu BR, Xiang JZ, Qian JQ. Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin 2005; 26: 1334-8.
48. Jain S K, Patel K, Rajpoot K, Jain A. Development of a berberine loaded multifunctional design for the treatment of Helicobacter pylori induced gastric ulcer. Drug Delivery Letters 2018; 8: 50-7.
49. Chen XX, Chen YX, Bi HX, et al. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori. J Dig Dis 2022; 23: 568-76.
50. Hu Q, Peng Z, Li LL, et al. The efficacy of berberine-containing quadruple therapy on Helicobacter pylori eradication in China: a systematic review and Meta-analysis of randomized clinical trials. Front Pharmacol 2020; 10: 1694.
51. Koci BD, Dimitrijevi MV, Miladinovi LC, et al. In vitro anti-Helicobacter pylori activity of berberine and barberry extracts: a preliminary report. Nat Prod Commun 2019; 14: 1934578X1985790.
52. Yang T, Wang RL, Zhang JZ, et al. Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressing. Life Sci 2020; 248: 117456.
53. Cheng H, Liu J, Tan YZ, Feng WW, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. J Pharm Anal 2022; 12: 541-55.
54. Habtemariam S. Berberine pharmacology and the gut microbiota: a hidden therapeutic link. Pharmacol Res 2020; 155: 104722.
55. Cui HX, Hu YN, Li JW, Yuan K, Guo Y. Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules 2018; 24: 103.
56. Wang H, Zhang HY, Gao ZZ, Zhang QQ, Gu CJ. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol 2022; 12: 854885.
57. Koperska A, Weso?ek A, Moszak M, Szulińska M. Berberine in non-alcoholic fatty liver disease-a review. Nutrients 2022; 14: 3459.
58. Guo Y, Zhang YC, Huang WH, Selwyn FP, Klaassen CD. Dose-response effect of berberine on bile acid profile and gut microbiota in mice. BMC Complement Altern Med 2016; 16: 394.
59. Zhang W, Xu JH, Yu T, Chen QK. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother 2019; 118: 109131.
60. Tian Y, Cai JW, Gui W, et al. Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation. Drug Metab Dispos 2019; 47: 86-93.
61. Wang Y, Shou JW, Li XY, et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism 2017; 70: 72-84.
62. Yan F, Wang LH, Shi Y, et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G504-14.
63. Dong YL, Fan H, Zhang Z, et al. Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway. Int J Biol Sci 2022; 18: 1381-97.
64. Lee IA, Hyun YJ, Kim DH. Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. Eur J Pharmacol 2010; 648: 162-70.
65. Jing WH, Dong SJ, Luo XL, et al. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. Pharmacol Res 2021; 164: 105358.
66. Liao ZQ, Xie YZ, Zhou BJ, et al. Berberine ameliorates colonic damage accompanied with the modulation of dysfunctional bacteria and functions in ulcerative colitis rats. Appl Microbiol Biotechnol 2020; 104: 1737-49.
67. Zheng C, Wang YM, Xu YJ, et al. Berberine inhibits dendritic cells differentiation in DSS-induced colitis by promoting Bacteroides fragilis. Int Immunopharmacol 2021; 101: 108329.
68. Habtemariam S. Berberine and inflammatory bowel disease: a concise review. Pharmacol Res 2016; 113: 592-9.
69. Li H, Fan C, Lu HM, et al. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions. Acta Pharm Sin B 2020; 10: 447-61.
70. Wang J, Wang L, Lou GH, et al. Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm Biol 2019; 57: 193-225.
71. Li G, Zhang C, Liang W, Zhang YB, Shen YH, Tian XH. Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. Pharm Biol 2021; 59: 21-30.
72. Hu Q, Li LL, Zou X, Xu LJ, Yi P. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front Pharmacol 2018; 9: 1150.
73. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
74. Yu YN, Yu TC, Zhao HJ, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget 2015; 6: 32013-26.
75. Och A, Podgórski R, Nowak R. Biological activity of berberine-A summary update. Toxins (Basel) 2020; 12: 713.
76. Hesari A, Ghasemi F, Cicero AFG, et al. Berberine: a potential adjunct for the treatment of gastrointestinal cancers? J Cell Biochem 2018; 119: 9655-63.
77. Almatroodi SA, Alsahli MA, Rahmani AH. Berberine: an important emphasis on its anticancer effects through modulation of various cell signaling pathways. Molecules 2022; 27: 5889.
78. Kou YY, Tong BD, Wu WQ, Liao XQ, Zhao M. Berberine improves chemo-sensitivity to cisplatin by enhancing cell apoptosis and repressing PI3K/AKT/mTOR signaling pathway in gastric cancer. Front Pharmacol 2020; 11: 616251.
79. Tarawneh N, Hamadneh L, Abu-Irmaileh B, Shraideh Z, Bustanji Y, Abdalla S. Berberine inhibited growth and migration of human colon cancer cell lines by increasing phosphatase and tensin and inhibiting aquaporins 1, 3 and 5 expressions. Molecules 2023; 28: 3823.
80. Li HL, Wu H, Zhang BB, Shi HL, Wu XJ. MAPK pathways are involved in the inhibitory effect of berberine hydrochloride on gastric cancer MGC 803 cell proliferation and IL-8 secretion in vitro and in vivo. Mol Med Rep 2016; 14: 1430-8.
81. Wang Y, Zhou MY, Shang D. Berberine inhibits human gastric cancer cell growth via deactivation of p38/JNK pathway, induction of mitochondrial-mediated apoptosis, caspase activation and NF-κB inhibition. J BUON 2020; 25: 314-8.
82. Zhang Q, Wang XB, Cao SJ, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomed Pharmacother 2020; 128: 110245.
83. Albring KF, Weidemüller J, Mittag S, et al. Berberine acts as a natural inhibitor of Wnt/β-catenin signaling--identification of more active 13-arylalkyl derivatives. Biofactors 2013; 39: 652-62.
84. Samadi P, Sarvarian P, Gholipour E, et al. Berberine: a novel therapeutic strategy for cancer. IUBMB Life 2020; 72: 2065-79.
85. Wang LH, Cao HL, Lu N, et al. Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PLoS One 2013; 8: e56666.
86. Liu X, Ji Q, Ye NJ, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE 2 Mediated JAK2/STAT3 signaling pathway. PLoS One 2015; 10: e0123478.
87. Li J, Wang Y, Chen D, Liu-Bryan R. Oral administration of berberine limits post-traumatic osteoarthritis development and associated pain via AMP-activated protein kinase (AMPK) in mice. Osteoarthritis Cartilage 2022; 30: 160-71.
88. Shen HR, Xu X, Li XL. Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reprod Biol Endocrinol 2021; 19: 3.
89. Karnam KC, Ellutla M, Bodduluru LN, et al. Preventive effect of berberine against DMBA-induced breast cancer in female Sprague Dawley rats. Biomed Pharmacother 2017; 92: 207-214.
90. Liu Y, Liu XJ, Zhang N, et al. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B 2020; 10: 2299-312.
91. Yang FJ, Gao RM, Luo XX, Liu RA, Xiong DQ. Berberine influences multiple diseases by modifying gut microbiota. Front Nutr 2023; 10: 1187718.
92. Deng JQ, Zhao LL, Yuan XY, et al. Pre-administration of berberine exerts chemopreventive effects in AOM/DSS-induced colitis-associated carcinogenesis mice via modulating inflammation and intestinal microbiota. Nutrients 2022; 14: 726.
93. Haththotuwa RN, Wijeyaratne CN, Senarath U. Obesity and obstetrics. 2nd ed. Netherlands: Elsevier, 2020: 3-8.
94. Park HJ, Jung E, Shim I. Berberine for appetite suppressant and prevention of obesity. Biomed Res Int 2020; 2020: 3891806.
95. Ilyas Z, Perna S, Al-Thawadi S, et al. The effect of berberine on weight loss in order to prevent obesity: a systematic review. Biomed Pharmacother 2020; 127: 110137.
96. Sun HL, Wang NJ, Cang Z, et al. Modulation of microbiota-gut-brain axis by berberine resulting in improved metabolic status in high-fat diet-fed rats. Obes Facts 2016; 9: 365-78.
97. Zhang X, Zhao YF, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 2015; 5: 14405.
98. Yue SJ, Wang WX, Zhang L, et al. Anti-obesity and gut microbiota modulation effect of Astragalus Polysaccharides combined with berberine on high-fat diet-fed obese mice. Chin J Integr Med 2023; 29: 617-25.
99. Kavyani Z, Shahhosseini E, Moridpour AH, et al. The effect of berberine supplementation on lipid profile and obesity indices: an umbrella review of Meta-analysis. PharmaNutrition 2023; 26: 100364.
100. Del Gaudio MP, Kraus SI, Melzer TM, Bustos PS, Ortega MG. Antinociceptive effect and identification of berberine alkaloid in Berberis ruscifolia extracts. J Ethnopharmacol 2023; 305: 116066.
101. Briand F, Thieblemont Q, Muzotte E, Sulpice T. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol 2013; 33: 13-23.
102. Shen N, Huan Y, Shen ZF. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol 2012; 694: 120-6.
103. Han YF, Xiang Y, Shi Y, et al. Pharmacokinetics and pharmacological activities of berberine in diabetes mellitus treatment. Evid Based Complement Alternat Med 2021; 2021: 9987097.
104. Feng XC, Wang K, Cao SJ, Ding LQ, Qiu F. Pharmacokinetics and excretion of berberine and its nine metabolites in rats. Front Pharmacol 2021; 11: 594852.
105. Solnier J, Zhang Y, Kuo YC, et al. Characterization and pharmacokinetic assessment of a new berberine formulation with enhanced absorption in vitro and in human volunteers. Pharmaceutics 2023; 15: 2567.
106. Ma JY, Feng R, Tan XS, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci 2013; 102: 4181-92
107. Jove M, Spencer J, Clench M, Loadman PM, Twelves C. Precision pharmacology: mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol 2019; 141: 153-62.
108. Li JQ, Zhang Q, Chen YT, Lu CY, Tong YB. Pharmacokinetics, tissue distribution and excretion of demethyleneberberine, a metabolite of berberine, in rats and mice. Molecules 2023; 28: 7725.
109. Ai XP, Yu PL, Peng LX, et al. Berberine: a review of its pharmacokinetics properties and therapeutic potentials in diverse vascular diseases. Front Pharmacol 2021; 12: 762654.
110. Guo Y, Pope C, Cheng X, Zhou H, Klaassen CD. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 2011; 138: 111-8.
111. Singh S, Pathak N, Fatima E, Negi AS. Plant isoquinoline alkaloids: advances in the chemistry and biology of berberine. Eur J Med Chem 2021; 226: 113839.
112. Zhang ZW, Cong L, Peng R, et al. Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota. J Pharm Anal 2021; 11: 628-37.
113. Wang K, Feng XC, Chai LW, Cao SJ, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev 2017; 49: 139-57.
114. Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 2016; 109: 274-82.
115. Lan JR, Zhao YY, Dong FX, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 2015; 161: 69-81.
116. Pang B, Zhao LH, Zhou Q, et al. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol 2015; 2015: 905749.
117. Yang SY, Wang XH. A research on the erupted fetal diseases caused by traditional Chinese drugs--discussion from the issue that Chinese goldthread rhizome is prohibited in Singapore. J Tradit Chin Med 2008; 28: 235-40.
118. Farooqi AA, Qureshi MZ, Khalid S, et al. Regulation of cell signaling pathways by berberine in different cancers: searching for missing pieces of an incomplete jig-saw puzzle for an effective cancer therapy. Cancers (Basel) 2019; 11: 478.
119. Zhao YW, Jing ZL, Li Y, Mao WF. Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. Oncol Rep 2016; 36: 567-72.
Options
Outlines

/

〈 〉